Study creates a complete list of relevant blood biomarkers for the early detection of cancer

Study creates a complete list of relevant blood biomarkers for the early detection of cancer -

The researchers identified 788 biomarkers in the blood that could be used to develop a screening test early stage of cancer in the general population.

study, conducted by the University of Sheffield, is the first to create a comprehensive list of relevant cancer blood biomarkers that have been investigated in the past five years. The study also has the group by molecular function and saves the technologies that can be used to detect

The team -. The universities of Sheffield, Coventry and Warwick - opened with more than 19,000 scientific studies published over the last five years which investigated the blood-based biomarkers. examination systematic methods - including power studies in patients under 50 -. reduced that to 4,000 studies from which the final list of biomarkers was compiled

Lead researcher, Dr Lesley Uttley, of Sheffield University School of Health and Related Research, said "because of the large number of publications in this area, previous reviews have only been able to watch a biomarker or a small group of biomarkers Our approach to data mining has allowed us to take in all search results relevant to the. five years, which means that we could map the full range of potential blood-based biomarkers that are particularly relevant for the early detection of cancer. "

work was conducted for the detection of early Consortium cancer, a group of nearly 40 organizations, including universities, hospitals, and commercial companies. The consortium was funded by the cancer research UK to determine whether a cost-effective screening test can be used in the general population to identify people with cancer at an early stage.

the next step is to examine in detail the research behind each biomarker, to ensure that it is robust and that the biomarker could realistically be used as part of a screening test. biomarkers are also grouped by type of cancer at this stage. validated biomarkers will then be put through a study clinic, using samples from cancer patients and healthy controls in order to verify to what extent they identify the presence of cancer.

Finally, these biomarkers that operate successfully in the study will be taken forward in a clinical trial to see if the test works in practice and is cost-effective

ECDC Director and molecular pathologist at the University Hospitals Coventry and Warwickshire NHS Trust, Professor Ian Cris said :. "Our expectation is that once the validation and clinical studies are completed, we will have a suite of 50 biomarkers identified using four different tests that can go into the clinical trial. To complete validation and testing will take six to eight years, but in theory, we could have a test ready in three years for use in high-risk groups. "

"Our vision is that the screen will resume even small amounts of these biomarkers could be in the blood at an early stage cancer, without necessarily identifying which cancers they relate. The patients would then be returned for more specific tests, which could limit the type of tumor. "